NeuroPace has announced that the first patient has been implanted with its responsive neurostimulation (RNS) System in the NAUTILUS clinical study to treat idiopathic generalised epilepsy (IGE).
The randomised, multicentre, prospective, controlled pivotal study has been designed to evaluate the RNS System’s effectiveness and safety as an adjunctive therapy for the treatment of IGE, also called primary generalised epilepsy.
It will be conducted in participants aged 12 years and above with hard-to-treat IGE.
